Impact of Genetic Variation on Response to GO Therapy in COG-AML Trials AAML03P1 and AAML0531

AFFECTION_STATUS - Case control status of the subject for primary acute myeloid leukemia (AML); all subjects are AML patients. (phv00555848.v1.p1)
ANALYTE_TYPE - Analyte Type (phv00555858.v1.p1)
BODY_SITE - Body site where sample was collected (phv00555857.v1.p1)
CONSENT - Consent group as determined by DAC (phv00555843.v1.p1)
DAYS_TO_EFS - Days to event-free survival (EFS) from study entry (phv00555854.v1.p1)
DAYS_TO_OS - Days to overall survival (OS) from study entry (phv00555852.v1.p1)
EFS_INDICATOR - Event-free survival (EFS) from study entry indicator (phv00555855.v1.p1)
OS_INDICATOR - Overall survival (OS) from study entry indicator (phv00555853.v1.p1)
SAMPLE_ID - Unique sample identifier (phv00555856.v1.p1)
SAMPLE_ID - Same as blinded subject ID (phv00555846.v1.p1)
SUBJECT_ID - Unique identifier assigned to subject by Children's Oncology Group (COG) (phv00555847.v1.p1)
SUBJECT_ID - Subject ID (phv00555842.v1.p1)
SUBJECT_ID - Blinded Subject ID (phv00555845.v1.p1)
TREATMENT_ARM - ADE or ADE+GO arm of combined AAML03P1 and AAML0531 cohort used in study (phv00555851.v1.p1)